Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (880)	12/13/2017 3:29:38 PM
From: tuck	Read Replies (1) \| Respond to of 897

While I'm talking of NASH failures, Intercept (ICPT) is bouncing on an analyst note that is likely overly rosy regarding chances of the REGENERATE trial's success and on the dollar amount of the PBC market (PBC is rare). Cheers, Tuck

To: tuck who wrote (880)	12/19/2017 8:46:07 PM
From: tuck	Respond to of 897

Galectin (GALT) fakes right (with shelf), goes left (gets line of credit from new - elected last week - Director). Nifty. There are warrants, and half of them vest immediately, but the strike price is $5. This buys them a bit over a year without immediate dilution, so the stock is fireworking after hours, spiking to $2.50. Reminds me of MannKind. Although that company at least got their product to market. I doubt GALT will. But that erases a decent profit on my position if it holds. To add on the spike? Might well. Cheers, Tuck